Diabetes

Sanofi announced that the FDA has accepted the New Drug Application (NDA) for Zynquista (sotagliflozin).

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Population-based screening was found to be associated with a reduction in admissions, physician visits, and prescribed medication for individuals diagnosed with type 2 diabetes.

CVS Health's Chief Medical Officer Troyen A. Brennan, MD, outlined how the combination of data-driven insights, and the convenience of community-based retail health care can provide a highly personalized health care experience that supports the primary care medical home, and can improve patient outcomes and lower costs.

Patients with diabetes taking canagliflozin achieved better glycemic control, were less likely to stop taking the medication, and were less likely to switch to another drug.

Upgrades to the insulin pen to improve disease management and prevent hypoglycemia due to overdoses are on the horizon.

In an additional analysis from the CANVAS program, new data reinforce evidence of improved renal outcomes for those with type 2 diabetes and chronic kidney disease.

One Drop is a company that has a great holistic service using CDE to help patients get their diabetes better controlled, and recent data support their mission.

The health insurer recently launched its Emerging Solutions' platform.

Certified Diabetes Educators (CDEs) can make a tremendous difference in the lives of people who have diabetes.

An artificial pancreas can improve blood sugar control for people with type 1 diabetes (T1D), according to a new study.

Researchers concluded that metformin may reduce risk of nonsevere statin muscle pain.

For its upcoming Directions in Pharmacy® conference in Nashville, Tennessee, Pharmacy Times Continuing EducationTM is partnering with Lilly USA, LLC to present “An Insulin Monotherapy Option for Patients on High Doses of Insulin.”

Officials with the FDA have approved marketing of the first medical device to use artificial intelligence (AI) to detect notable eye disease diabetic retinopathy (DR) in adults with diabetes.

US report indicates new drivers of death have emerged over time and have continued to unequally affect residents at the state level.

Sanofi plans to offer a discount for some patients with diabetes who are uninsured or who have high-deductible insurance plans.

Smart socks, such as those from Siren, seek to help identify infections, and ulcers before they happen, but the data is lacking. Are they worth it?

Exenatide extended-release (Bydureon) approved as an add-on therapy to basal insulin in adults with type 2 diabetes with inadequate glycemic control.

Long-term use of dietary supplements may improve C-reactive protein, HDL cholesterol, serum homocysteine, blood pressure, and incidence of diabetes.

A number of complementary and alternative medications can potentially lower blood sugar, and many patients with diabetes look at these substances as more natural than synthetic drugs.

Newly-approved device could reduce the amount of pens adults prescribed to Toujeo need to use.

Top news of the week from The American Journal of Pharmacy Benefits.

In this clip, Traci Fritschle, PharmD, explains why pharmacists are uniquely positioned to be utilized in a team-based model for diabetes care.